Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Spontaneous Mutations of Bcor and Jak1/2 genes Lead to an Aggressive Leukemia of B-1 Progenitor B Cells

Sheryl M Gough, PhD BSc, Liat Goldberg, PhD, Marbin Pineda, MS, Robert L Walker, BSc, Yuelin J Zhu, MD MSc, Sven Bilke, PhD, Paul S Meltzer, MD PhD, Peter D Aplan, MD

Blood (2014) 124 (21): 3573.

https://doi.org/10.1182/blood.V124.21.3573.3573

Published: 2014

Journal Articles

Results of a Phase 2 Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, In Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia Myelofibrosis

Rami S. Komrokji, MD, Martha Wadleigh, MD, John F. Seymour, MD, PhD, Andrew W. Roberts, MD, PhD, Luen Bik To, Huan J. Zhu, MD, PhD, Ruben A. Mesa, MD

Blood (2011) 118 (21): 282.

https://doi.org/10.1182/blood.V118.21.282.282

Published: 2011

Journal Articles

Phase I Dose-Escalation Trial of SB1518, a Novel JAK2/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia/ Polycythemia Vera Myelofibrosis.

Srdan Verstovsek, MD, PhD, Olatoyosi Odenike, MD, Bart Scott, MD, Zeev Estrov, MD, Jorge Cortes, MD, Deborah A. Thomas, MD, Jeanette Wood, PhD, Kantharaj Ethirajulu, PhD, Ann Lowe, MD, Huan J. Zhu, MD, PhD, Hagop Kantarjian, MD, H. Joachim Deeg, MD

Blood (2009) 114 (22): 3905.

https://doi.org/10.1182/blood.V114.22.3905.3905

Published: 2009

Journal Articles

Phase-I Study of the Novel Oral JAK-2 Inhibitor SB1518 in Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity.

Anas Younes, MD, Michelle Fanale, M.D., Peter McLaughlin, Amanda R Copeland, MS, Silvana de Castro Faria, Jeanette Wood, PhD, Kantharaj Ethirajulu, PhD, Huan J. Zhu, MD, PhD

Blood (2009) 114 (22): 588.

https://doi.org/10.1182/blood.V114.22.588.588

Published: 2009

Journal Articles

Phase II Trial of SCIO-469 as Monotherapy (M) or in Combination with Bortezomib (MB) in Relapsed Refractory Multiple Myeloma (MM).

Blood (2006) 108 (11): 3580.

https://doi.org/10.1182/blood.V108.11.3580.3580

Published: 2006

NARROW

Spontaneous Mutations of Bcor and Jak1/2 genes Lead to an Aggressive Leukemia of B-1 Progenitor B Cells

Results of a Phase 2 Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, In Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia Myelofibrosis

Phase I Dose-Escalation Trial of SB1518, a Novel JAK2/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia/ Polycythemia Vera Myelofibrosis.

Phase-I Study of the Novel Oral JAK-2 Inhibitor SB1518 in Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity.

Phase II Trial of SCIO-469 as Monotherapy (M) or in Combination with Bortezomib (MB) in Relapsed Refractory Multiple Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

Spontaneous Mutations of Bcor and Jak1/2 genes Lead to an Aggressive Leukemia of B-1 Progenitor B Cells

Results of a Phase 2 Study of Pacritinib (SB1518), a Novel Oral JAK2 Inhibitor, In Patients with Primary, Post-Polycythemia Vera, and Post-Essential Thrombocythemia Myelofibrosis

Phase I Dose-Escalation Trial of SB1518, a Novel JAK2/FLT3 Inhibitor, in Acute and Chronic Myeloid Diseases, Including Primary or Post-Essential Thrombocythemia/ Polycythemia Vera Myelofibrosis.

Phase-I Study of the Novel Oral JAK-2 Inhibitor SB1518 in Patients with Relapsed Lymphoma: Evidence of Clinical and Biologic Activity.

Phase II Trial of SCIO-469 as Monotherapy (M) or in Combination with Bortezomib (MB) in Relapsed Refractory Multiple Myeloma (MM).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only